Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $11.41 million. The enterprise value is $5.47 million.
| Market Cap | 11.41M |
| Enterprise Value | 5.47M |
Important Dates
The last earnings date was Thursday, May 14, 2026, after market close.
| Earnings Date | May 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 3.66 million shares outstanding. The number of shares has increased by 57.98% in one year.
| Current Share Class | 3.66M |
| Shares Outstanding | 3.66M |
| Shares Change (YoY) | +57.98% |
| Shares Change (QoQ) | +19.63% |
| Owned by Insiders (%) | 3.19% |
| Owned by Institutions (%) | 9.56% |
| Float | 3.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.25 |
| Forward PS | 27.39 |
| PB Ratio | 0.76 |
| P/TBV Ratio | 1.32 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 7.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.28, with a Debt / Equity ratio of 0.13.
| Current Ratio | 2.28 |
| Quick Ratio | 1.94 |
| Debt / Equity | 0.13 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -151.66% and return on invested capital (ROIC) is -322.26%.
| Return on Equity (ROE) | -151.66% |
| Return on Assets (ROA) | -52.09% |
| Return on Invested Capital (ROIC) | -322.26% |
| Return on Capital Employed (ROCE) | -185.53% |
| Weighted Average Cost of Capital (WACC) | 16.51% |
| Revenue Per Employee | $6,245 |
| Profits Per Employee | -$421,763 |
| Employee Count | 115 |
| Asset Turnover | 0.02 |
| Inventory Turnover | 0.41 |
Taxes
| Income Tax | -1.63M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -60.26% in the last 52 weeks. The beta is 2.75, so Co-Diagnostics's price volatility has been higher than the market average.
| Beta (5Y) | 2.75 |
| 52-Week Price Change | -60.26% |
| 50-Day Moving Average | 3.26 |
| 200-Day Moving Average | 6.30 |
| Relative Strength Index (RSI) | 43.40 |
| Average Volume (20 Days) | 5,281,057 |
Short Selling Information
The latest short interest is 349,389, so 9.55% of the outstanding shares have been sold short.
| Short Interest | 349,389 |
| Short Previous Month | 194,179 |
| Short % of Shares Out | 9.55% |
| Short % of Float | 9.87% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $718,166 and -$48.50 million in losses. Loss per share was -$29.82.
| Revenue | 718,166 |
| Gross Profit | 323,611 |
| Operating Income | -31.94M |
| Pretax Income | -50.13M |
| Net Income | -48.50M |
| EBITDA | -30.86M |
| EBIT | -31.94M |
| Loss Per Share | -$29.82 |
Balance Sheet
The company has $8.23 million in cash and $2.03 million in debt, with a net cash position of $6.20 million or $1.70 per share.
| Cash & Cash Equivalents | 8.23M |
| Total Debt | 2.03M |
| Net Cash | 6.20M |
| Net Cash Per Share | $1.70 |
| Equity (Book Value) | 16.04M |
| Book Value Per Share | 4.45 |
| Working Capital | 5.50M |
Cash Flow
| Operating Cash Flow | -28.24M |
| Capital Expenditures | -750,151 |
| Depreciation & Amortization | 1.10M |
| Net Borrowing | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 45.06% |
| Operating Margin | -4,447.41% |
| Pretax Margin | -6,980.30% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -57.98% |
| Shareholder Yield | -57.98% |
| Earnings Yield | -415.72% |
| FCF Yield | n/a |
Analyst Forecast
The average price target for Co-Diagnostics is $45.00, which is 1,342.31% higher than the current price. The consensus rating is "Hold".
| Price Target | $45.00 |
| Price Target Difference | 1,342.31% |
| Analyst Consensus | Hold |
| Analyst Count | 1 |
| Revenue Growth Forecast (3Y) | 356.88% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 2, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jan 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Co-Diagnostics has an Altman Z-Score of -9.03 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -9.03 |
| Piotroski F-Score | 1 |